The pharmaceutical contract manufacturing market is estimated to be worth USD 141 billion in 2030, growing at a CAGR of 6.1%, during the period 2021-2025, and 7.3%, over the period 2026-2030. It is worth highlighting that the outsourced component of t
The pharmaceutical API manufacturing market is likely to be worth USD 93 billion in 2030, growing at a CAGR of 6.4%. Further, the outsourced component of the pharmaceutical FDF manufacturing is likely to be worth USD 48 billion in 2030, growing at a CAGR of 7.3% during the forecast period.
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/pharmaceutical-contract-manufacturing-market/191.html
In terms of the type of dosage form, the contract manufacturing market for oral solid dosage form is projected to reach USD 14 billion, in 2030, growing at a CAGR of 2.7%. Interestingly, the revenues generated from parenteral dosage form are projected to increase from USD 6.9 billion in 2021 to USD 19 billion in 2030, growing at a CAGR of 12%.
Since pharmaceutical contract manufacturing market is an established domain, with presence of numerous commercial products, the pharmaceutical contract manufacturing market for commercial scale of operation is likely to be worth USD 114 billion in 2030, growing at a CAGR of 5.9%, while the market for clinical scale of operation is likely to be worth USD 27 billion in 2030, growing at a CAGR of 11%. It is worth highlighting that clinical-stage products are anticipated to account for around 20% of the overall revenue share in 2030.
It must be noted that according to our base case projections, the pharmaceutical contract manufacturing market for parenteral / injectable form of packaging is likely to be worth USD 48 billion in 2030, growing at a CAGR of 13%, during the forecast period. Further, the contract manufacturing market for bottles and blister packaging is likely to be worth USD 30 billion and USD 25 billion, respectively, in 2030.
According to our base case projections, the pharmaceutical contract manufacturing market for large and very large players is likely to be worth USD 72 billion, in 2030. This can be attributed to the fact that these companies offer their products across various therapeutic areas. Further, the revenues generated from mid-sized and small pharmaceutical companies are likely to be worth USD 37 billion and USD 32 billion, respectively, in 2030. It is worth highlighting that the share of small pharmaceutical companies in the overall contract manufacturing market is anticipated to increase from 20% in 2021 to 23% in 2030.
It is worth mentioning that in terms of geographical distribution, the pharmaceutical contract manufacturing markets in North America and Europe are likely to grow at a CAGR of 6.6% and 5.9%, respectively. On the other hand, the emerging markets within the Asia-Pacific, Latin America, and Middle East and North Africa regions are estimated to grow at a CAGR of 7.3%, 5.1% and 7%, respectively.
You may also be interested in the following reports:
- Peptide Therapeutics
- Biopharmaceutical Excipient Manufacturing Market
- Single-use Sensors for Bioprocessing Market
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook – https://www.facebook.com/RootsAnalysis
LinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter – https://twitter.com/RootsAnalysis
Medium – https://medium.com/@RootsAnalysis
Pinterest – https://in.pinterest.com/RootsanalysisPin/_saved/
Quora – https://rootsanalysisinsights.quora.com/
